A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Tag: dabigatran

  • Pradaxa – Interruption for Colonoscopy, Dental Work, Surgery, etc.

    When to stop the drug – General comments If you are on Pradaxa® (Dabigatran) you may need interruption of therapy for dental work, a medical procedure such as colonoscopy, or minor or major surgical procedure. As to when exactly to take the last dose of Pradaxa® before the procedure depends on (a) how big a…

  • Hair Loss on Warfarin

    How common is it? Hair loss is a known side effect of warfarin (Coumadin®, Jantoven®), but has hardly been studied [ref 1]. Solid data on how frequently it occurs, on its time-course, and on treatments are  not available. Mild hair loss appears to be common, severe hair loss uncommon, complete hair loss has not been…

  • INRs that Fluctuate – Solutions

    Background and summary The cause  of fluctuating INRs in patients on warfarin is often not clear.  The following causes should be considered. Solutions how to deal with fluctuating INRs are listed further below.

  • Pradaxa – Management of Major Bleeding

    Major and life-threatening bleeding is expected to occur in some patients treated with Pradaxa® (=Dabigatran). The question will then urgently arise how to best treat such catastrophic bleeding.

  • Pradaxa – Management of Major Bleeding

    Major and life-threatening bleeding is expected to occur in some patients treated with Pradaxa® (=Dabigatran). The question will then urgently arise how to best treat such catastrophic bleeding.  As there have been no data published on this topic in the peer-reviewed medical literature, we don’t know how to best manage a patient with major and…

  • Pradaxa Approval – Great News!

    The new oral anticoagulant Pradaxa® (Dabigatran) was approved by the FDA on October 20th, 2010 [ref 1,2]. As of Feb 3rd, 2012, Pradaxa® is only FDA approved for use in patients with atrial fibrillation. It is not approved yet for patients with DVT and PE.

  • Pradaxa approval – Great news!

    Summary The new oral “blood thinner” Pradaxa® (=Dabigatran) was approved by the FDA on October 20th, 2010 (ref 1 and 2). This is huge news! This is the first oral blood thinner alternative to warfarin (=Coumadin®, Jantoven®). At this point, Pradaxa® is only FDA approved for use in patients with irregular heart beat (= atrial…